Tell me if you heard this story before. Merger Monday and nothing happens in biotech. We have essentially run out of excuses as it was the political uncertainty and then it was tax reform. Neither are issues at the moment and we still have nothing happening. Are valuations in public companies still too high? Have […]
October 10 Biotech Update
I do not think there is much to say today outside of the obvious. The market is not looking good and we seem to be entering (or in the midst) of a broad market correction that is going to take everything down with it. Fundamentals are not going to matter in the near term. It […]
October 5 Biotech Update
Yesterday was brutal to say the least. There really was nothing to like about it. The XBI seems to have broken below its range and the IBB is rushing to the bottom end of its range. I have been talking about the XBI as the early warning index for the IBB and unless it can […]
SRPT – Again, WMS-2018 Dystrophin Data Beating the Market Expectation
Yesterday 10/04, at 7:00 am ET, Sarepta Therapeutics (SRPT) with Dr. Mendell released the biopsy data from the fourth patient including full 4 patients “Functional Data” from Argentina at #WMS2018 the 23rd International Annual World Muscle Society meeting Link to the full slide deck: https://www.sec.gov/Archives/edgar/data/873303/000119312518292068/d616670dex992.htm The after-hours share price reaction was wild swing, spiking up […]
SRPT – Preparing for WMS-2018 Presentation
Tomorrow 10/04, at 7:00 am ET, Sarepta Therapeutics (SRPT) with Dr. Mendell are hosting a conference call from Argentina at #WMS2018 the 23rd International Annual World Muscle Society meeting, to present and discuss new data from the micro-dystrophin gene-therapy study Ph1/2. Link to SRPT webcast page: http://investorrelations.sarepta.com/events-and-presentations Back in June 19th at the R&D day SRPT […]
September 24 Biotech Update
An interesting start to the week, although we still like real M&A or business development. Unlike previous weeks, however, there is actually some interesting news to discuss. The sector is green and outperforming the broader market but the move seems pretty isolated so ideally this green will broaden as the day continues. 1. The big […]
SRPT’s CEO Fireside Chat at Morgan Stanley Conference
Sarepta (SRPT) had a great run last week, a kick off following MS fireside chat, closing at $152.76 the highest “close” since June 21st (highest 52W close 06/20 was $153.69) on nice volume, but the highest “Weekly-Close” in the weekly chart (Close & not highest price point). Looking for a continuation next week, while the target […]
September 13th Biotech Update
We are finally getting a broad snap back rally but it needs to be more than a simple morning rally that is faded as the day goes along. If this rally is not built upon during the day, then odds are it simply reset the RSI and opened up a path to retest the bottom […]
September 12th Biotech Update
The sector is certainly struggling and its inability to generate any consistent buying interest after the sell-off is certainly worrisome. All of that being said there are so many names that have been red everyday that there has to be a snap back rally at a minimum. CELG has lost over $1.2B in market cap […]
August 16th Biotech Update
The sector was pretty weak yesterday but remained in its range. While there is nothing to dissuade me from the summer chop, there are some warning signs. First, we are close to breaking through the support on both the XBI and IBB. Second, the early morning bounce was quickly sold. Obviously it remains early but […]
August 9th Biotech Update
The chop continues. I just do not see anything definitive in either direction and am coming around to the belief that we are not going to see anything definitive soon. I suspect we bounce between 113 and 120 on the IBB for a bit and then come the fall we see a break with volume […]
August 8th Biotech Update
We are not quite getting the clarity to the upside but there is nothing to indicate that the sector is about to break to the downside. It seems like the path of least resistance is going to be chop perhaps until more investors get back from their summer vacations. The fall tends to see more […]
XENE – Epilepsy and Advocacy Under the New FDA
Xenon Pharmaceuticals (XENE) is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapeutics for neurological disorders. XENE has an extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, focusing their efforts on novel product pipeline of CNS-central nervous system therapies, to address areas of high […]
FDA GT Draft Guidance is Bullish for Sarepta's DMD Pivotal Trial
Yesterday July 11, 2018 the FDA FDA issues 6 new draft guidance documents for gene therapy, clinical development and manufacturing guidance. Human Gene Therapy for Rare Diseases – FDA Draft Guidance for Industry https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610802.pdf The FDA guidance noting the pre-existing antibody to GT, this is the strongest SRPT’s & Dr. Mendell point, choosing the AAVrh74 which […]
SRPT – Building a Precision Genetic Medicine Powerhouse
Sarepta Therapeutics (SRPT) is attempting to build the most meaningful precision genetic medicine company in the world, and has laid out its strategy to investors of exactly how it plans to get there. It starts with Duchenne Muscular Dystrophy (DMD) and the goal of dramatically changing patients’ lives. The company may have just done that. […]
June 21 Biotech Update
Sector strength continued and is clearly outperforming the broader market. While we have seen this happen for a couple days before, this feels more like a real breakout. Ideally, we would need to pullback and test the previous resistance and have it act as support to confirm the move but I suspect it would hold. […]
June 20 Biotech Update
You would think replacing a computer would be an easy job, it apparently requires different layers of people and so not everyone was on campus yesterday. So at some point in the future I have to look forward to the computer replacement process to eat half of my day. In any case, at least the […]
June 19 Biotech Update
The trade war is taking a lot of the headlines and I am running out of time to write as they are replacing my computer soon, which will likely take a lot more time that it reasonably should but I wanted to write a quick note. 1. SRPT hit a grand slam. Not only did […]
June 18 Biotech Update
Nothing new to start the week outside of a pretty weak market. I am not sure what the catalyst outside of an extended market but it looks again like the sector is hitting resistance and unable to break out. Perhaps there is continued disappoint in term of the lack of deals but regardless of the […]
June 13 Biotech Update
The sector had a decent day, although participation was not great. We seem to be on the verge of breaking higher (at least in the XBI) but it will be difficult to do unless the rally is broader in its scope. Of course, one cannot complain too much given that we are generally moving higher […]
